Titterton Lewis H jr purchased $42K of ANIX

Titterton Lewis H jr purchased 12,000 shares of Anixa Biosciences Inc (ANIX) at $3.47 on 2026-07-20.

Original reporting
SEC EDGAR · Titterton Lewis H jr
Published Jul 20, 2026, 10:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 20, 2026, 10:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ANIX
Bullish
medium confidence
Mentioned
$ANIX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIXBullishLow
01

Why it matters

A new insider open-market purchase was disclosed at a specific price and share count, which can modestly influence sentiment but does not, by itself, change fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a major repricing without additional operational catalysts.

03

What to watch

The filing does not state intent, timing constraints, or whether the purchase is part of a broader pattern; traders should compare with prior Form 4 activity and overall volume/liquidity.

Relevance 4/10Novelty 5/10Timing: Filed on 2026-07-20, same day as the reported purchase date.

Background

This is an SEC Form 4 insider transaction for Anixa Biosciences, reported by a director.

Company-level read

Ticker impact

$ANIXBullishMedium confidence
Context

Director Titterton Lewis H jr filed a Form 4 open-market purchase of 12,000 ANIX shares at $3.4700 on 2026-07-20.

Expected impact

Likely limited near-term impact; may slightly support sentiment if traders treat insider buying as a signal.

Evidence & confidence

Form 4 confirms a new transaction today, yet it does not include guidance, trial results, contracts, or other company-specific fundamentals that typically drive repricing.

Market effects

Minimal, as this is a single-company insider transaction without sector-wide information.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine or driven by diversification, liquidity needs, or non-informational factors, especially without a 10b5-1 plan.

Key entities

  • Anixa Biosciences Inc

    Subject of the Form 4 insider transaction, ticker ANIX.

  • Titterton Lewis H jr

    Director who reported an open-market purchase of 12,000 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ANIXMedAI 8/10

Anixa ovarian cancer trial to be presented at ESMO congress

Anixa Biosciences (NASDAQ:ANIX) will present Phase 1 trial results for its ovarian cancer treatment at the ESMO congress. The trial, led by Dr. Robert Wenham, evaluates the safety and efficacy of liraltagene autoleucel, a CAR-T therapy. The company reported no dose-limiting toxicities, stable disease in one patient, and over one-year survival in four patients. Anixa plans to advance to a sixth cohort with a 1,000-fold dose increase.

$ANIXMedAI 8/10

Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026

Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Robert Wenham will present Phase 1 trial results of its CAR-T therapy for ovarian cancer at the ESMO Congress in December 2026. The trial, conducted at Moffitt Cancer Center, has completed its fifth cohort with no dose-limiting toxicities and encouraging preliminary results. The company plans to advance to a sixth cohort with a higher dose.

$ANIXMedAI 8/10

Four patients have survived over a year after treatment, one beyond two years. Anixa's trial will be presented Dec. 14.

Anixa Biosciences reported positive interim results from its Phase 1 trial of lira-cel, a CAR-T therapy for ovarian cancer. Four patients survived over a year, one beyond two years. The company plans to advance to a sixth cohort with a 1,000-fold dose increase. Results will be presented at the ESMO Immuno-Oncology & Advanced Therapies Congress on Dec. 14.

$ANIXLowAI 8/10

Anixa completes fifth cohort dosing in ovarian cancer trial

Anixa Biosciences (NASDAQ:ANIX) completed dosing the fifth cohort in its Phase 1 trial for ovarian cancer, with no dose-limiting toxicities observed. The fifth cohort received the highest dose yet, and one patient showed stable disease 90 days post-treatment. The sixth cohort will evaluate an even higher dose. The trial, conducted at Moffitt Cancer Center, aims to assess safety, tolerability, and preliminary efficacy.

$ANIXMedAI 8/10

Four ovarian cancer patients lived over a year after Anixa's experimental treatment.

Anixa Biosciences' experimental ovarian cancer treatment, lira-cel, showed promising results in a Phase 1 trial, with four patients surviving over a year. Dr. Jose Conejo-Garcia, who invented the technology, will present findings at the 2026 Ovarian Cancer Midwest Focus Conference. The trial, conducted with Moffitt Cancer Center, has not reported dose-limiting toxicities, and one patient has survived beyond two years.